论文部分内容阅读
目的探讨微卡(M.Vaccat)治疗老年反复呼吸道感染(RRI)的疗效。方法选择门诊就诊的老年反复呼吸道感染60例,随机分为微卡组与对照组,急性发作期均予以常规抗感染及对症支持治疗。微卡组在此基础上肌注微卡制剂22.5μg,每2周1针,连续3针。比较两组急性发作期主要症状及体征的消失时间,观察临床疗效及不良反应。结果微卡组治疗期发热、咳嗽和肺部啰音等主要症状及体征消失时间明显低于对照组(P<0.01)。微卡组治疗期间未发生严重的药物不良反应,其临床疗效高于对照组(P<0.05)。结论微卡治疗老年反复呼吸道感染的疗效及安全性较好,能明显缓解患者急性发作期的临床症状及体征。
Objective To investigate the efficacy of M.Vaccat in the treatment of recurrent respiratory tract infections (RRI) in the elderly. Methods Sixty elderly patients with recurrent respiratory tract infection were selected and randomly divided into micro-card group and control group. All patients were given routine anti-infective and symptomatic supportive care during acute exacerbation. On this basis, the micro-card group was intramuscularly injected with 22.5 μg of micro-card preparation, with 1 needle every 2 weeks and 3 consecutive needles. The disappearance time of the main symptoms and signs of acute exacerbation were compared between two groups to observe the clinical efficacy and adverse reactions. Results The main symptoms such as fever, cough and pulmonary rales in the microchip group during treatment were significantly lower than those in the control group (P <0.01). There was no serious adverse drug reaction during the treatment of micro-card group, and its clinical efficacy was higher than that of the control group (P <0.05). Conclusion Micro-card treatment of elderly patients with recurrent respiratory tract infection with good efficacy and safety, can significantly alleviate the clinical symptoms and signs of patients with acute attack.